Dr Tycell Phillips discusses the phase 2 GLOVe trial, combining the CD20/CD3 bispecific antibody glofitamab with venetoclax and lenalidomide for first-line high-risk mantle cell lymphoma (MCL).

He highlights a 100% complete response rate and 95% undetectable minimal residual disease (uMRD) after short follow-up, with manageable cytokine release syndrome (CRS) and no disease progression observed in the study cohort.